Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects

Anne Sofie Andreasen; Nadja Larsen; Theis Pedersen-Skovsgaard; Ronan M G Berg; Kirsten Møller; Kira Dynnes Svendsen; Mogens Jakobsen; Bente Klarlund Pedersen

doi:10.1017/S0007114510002874

Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects

Anne Sofie Andreasen, Nadja Larsen, Theis Pedersen-Skovsgaard, Ronan M G Berg, Kirsten Møller, Kira Dynnes Svendsen, Mogens Jakobsen, Bente Klarlund Pedersen

209 Citations (Scopus)

Abstract

According to animal studies, intake of probiotic bacteria may improve glucose homeostasis. We hypothesised that probiotic bacteria improve insulin sensitivity by attenuating systemic inflammation. Therefore, the effects of oral supplementation with the probiotic bacterium Lactobacillus acidophilus NCFM on insulin sensitivity and the inflammatory response were investigated in subjects with normal or impaired insulin sensitivity. In a double-blinded, randomised fashion, forty-five males with type 2 diabetes, impaired or normal glucose tolerance were enrolled and allocated to a 4-week treatment course with either L. acidophilus NCFM or placebo. L. acidophilus was detected in stool samples by denaturating gradient gel electrophoresis and real-time PCR. Separated by the 4-week intervention period, two hyperinsulinaemic-euglycaemic clamps were performed to estimate insulin sensitivity. Furthermore, the systemic inflammatory response was evaluated by subjecting the participants to Escherichia coli lipopolysaccharide injection (0·3 ng/kg) before and after the treatment course. L. acidophilus NCFM was detected in 75 % of the faecal samples after treatment with the probiotic bacterium. Insulin sensitivity was preserved among volunteers in the L. acidophilus NCFM group, whereas it decreased in the placebo group. Both baseline inflammatory markers and the systemic inflammatory response were, however, unaffected by the intervention. In conclusion, intake of L. acidophilus NCFM for 4 weeks preserved insulin sensitivity compared with placebo, but did not affect the systemic inflammatory response.

Original language	English
Journal	The British Journal of Nutrition
Volume	104
Issue number	12
Pages (from-to)	1831-8
Number of pages	8
DOIs	https://doi.org/10.1017/S0007114510002874
Publication status	Published - 28 Dec 2010

Keywords

Aged
Blood Glucose
Diabetes Mellitus, Type 2
Double-Blind Method
Feces
Humans
Inflammation
Insulin Resistance
Lactobacillus acidophilus
Male
Middle Aged
Probiotics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1017/S0007114510002874

Cite this

@article{abc4dea99ee741a5be2c3d9429f40fcd,

title = "Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects",

abstract = "According to animal studies, intake of probiotic bacteria may improve glucose homeostasis. We hypothesised that probiotic bacteria improve insulin sensitivity by attenuating systemic inflammation. Therefore, the effects of oral supplementation with the probiotic bacterium Lactobacillus acidophilus NCFM on insulin sensitivity and the inflammatory response were investigated in subjects with normal or impaired insulin sensitivity. In a double-blinded, randomised fashion, forty-five males with type 2 diabetes, impaired or normal glucose tolerance were enrolled and allocated to a 4-week treatment course with either L. acidophilus NCFM or placebo. L. acidophilus was detected in stool samples by denaturating gradient gel electrophoresis and real-time PCR. Separated by the 4-week intervention period, two hyperinsulinaemic-euglycaemic clamps were performed to estimate insulin sensitivity. Furthermore, the systemic inflammatory response was evaluated by subjecting the participants to Escherichia coli lipopolysaccharide injection (0·3 ng/kg) before and after the treatment course. L. acidophilus NCFM was detected in 75 % of the faecal samples after treatment with the probiotic bacterium. Insulin sensitivity was preserved among volunteers in the L. acidophilus NCFM group, whereas it decreased in the placebo group. Both baseline inflammatory markers and the systemic inflammatory response were, however, unaffected by the intervention. In conclusion, intake of L. acidophilus NCFM for 4 weeks preserved insulin sensitivity compared with placebo, but did not affect the systemic inflammatory response.",

keywords = "Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Feces, Humans, Inflammation, Insulin Resistance, Lactobacillus acidophilus, Male, Middle Aged, Probiotics",

author = "Andreasen, {Anne Sofie} and Nadja Larsen and Theis Pedersen-Skovsgaard and Berg, {Ronan M G} and Kirsten M{\o}ller and Svendsen, {Kira Dynnes} and Mogens Jakobsen and Pedersen, {Bente Klarlund}",

year = "2010",

month = dec,

day = "28",

doi = "10.1017/S0007114510002874",

language = "English",

volume = "104",

pages = "1831--8",

journal = "British Journal of Nutrition",

issn = "0007-1145",

publisher = "Cambridge University Press",

number = "12",

}

TY - JOUR

T1 - Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects

AU - Andreasen, Anne Sofie

AU - Larsen, Nadja

AU - Pedersen-Skovsgaard, Theis

AU - Berg, Ronan M G

AU - Møller, Kirsten

AU - Svendsen, Kira Dynnes

AU - Jakobsen, Mogens

AU - Pedersen, Bente Klarlund

PY - 2010/12/28

Y1 - 2010/12/28

N2 - According to animal studies, intake of probiotic bacteria may improve glucose homeostasis. We hypothesised that probiotic bacteria improve insulin sensitivity by attenuating systemic inflammation. Therefore, the effects of oral supplementation with the probiotic bacterium Lactobacillus acidophilus NCFM on insulin sensitivity and the inflammatory response were investigated in subjects with normal or impaired insulin sensitivity. In a double-blinded, randomised fashion, forty-five males with type 2 diabetes, impaired or normal glucose tolerance were enrolled and allocated to a 4-week treatment course with either L. acidophilus NCFM or placebo. L. acidophilus was detected in stool samples by denaturating gradient gel electrophoresis and real-time PCR. Separated by the 4-week intervention period, two hyperinsulinaemic-euglycaemic clamps were performed to estimate insulin sensitivity. Furthermore, the systemic inflammatory response was evaluated by subjecting the participants to Escherichia coli lipopolysaccharide injection (0·3 ng/kg) before and after the treatment course. L. acidophilus NCFM was detected in 75 % of the faecal samples after treatment with the probiotic bacterium. Insulin sensitivity was preserved among volunteers in the L. acidophilus NCFM group, whereas it decreased in the placebo group. Both baseline inflammatory markers and the systemic inflammatory response were, however, unaffected by the intervention. In conclusion, intake of L. acidophilus NCFM for 4 weeks preserved insulin sensitivity compared with placebo, but did not affect the systemic inflammatory response.

AB - According to animal studies, intake of probiotic bacteria may improve glucose homeostasis. We hypothesised that probiotic bacteria improve insulin sensitivity by attenuating systemic inflammation. Therefore, the effects of oral supplementation with the probiotic bacterium Lactobacillus acidophilus NCFM on insulin sensitivity and the inflammatory response were investigated in subjects with normal or impaired insulin sensitivity. In a double-blinded, randomised fashion, forty-five males with type 2 diabetes, impaired or normal glucose tolerance were enrolled and allocated to a 4-week treatment course with either L. acidophilus NCFM or placebo. L. acidophilus was detected in stool samples by denaturating gradient gel electrophoresis and real-time PCR. Separated by the 4-week intervention period, two hyperinsulinaemic-euglycaemic clamps were performed to estimate insulin sensitivity. Furthermore, the systemic inflammatory response was evaluated by subjecting the participants to Escherichia coli lipopolysaccharide injection (0·3 ng/kg) before and after the treatment course. L. acidophilus NCFM was detected in 75 % of the faecal samples after treatment with the probiotic bacterium. Insulin sensitivity was preserved among volunteers in the L. acidophilus NCFM group, whereas it decreased in the placebo group. Both baseline inflammatory markers and the systemic inflammatory response were, however, unaffected by the intervention. In conclusion, intake of L. acidophilus NCFM for 4 weeks preserved insulin sensitivity compared with placebo, but did not affect the systemic inflammatory response.

KW - Aged

KW - Blood Glucose

KW - Diabetes Mellitus, Type 2

KW - Double-Blind Method

KW - Feces

KW - Humans

KW - Inflammation

KW - Insulin Resistance

KW - Lactobacillus acidophilus

KW - Male

KW - Middle Aged

KW - Probiotics

U2 - 10.1017/S0007114510002874

DO - 10.1017/S0007114510002874

M3 - Journal article

C2 - 20815975

SN - 0007-1145

VL - 104

SP - 1831

EP - 1838

JO - British Journal of Nutrition

JF - British Journal of Nutrition

IS - 12

ER -

Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this